Rabies
Phase 3Biologic
NovartisRabies is one of 29 biologic programs targeting Japanese encephalitis. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
49 competitors in Japanese Encephalitis
#DrugCompanyPhaseTrials
1Prevnar
GSKPhase 3
Hepatitis a Vaccine
SanofiPhase 3
Havrix
GSKPhase 3
Measles Vaccine
GSKPhase 3
Rituxan
RochePhase 2
Measles-Mumps-Rubella Vaccine
LLiaoning Chengda Biotechnology CO., LTD
Approved
Virazole
CConrado Roberto Hoffmann Filho
Phase 2
Varicella Vaccine
SanofiPhase 3
Immunoglobulin
SanofiPhase 2
Japanese Encephalitis Vaccine
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Japanese encephalitis1 trial
Immunogenicity1 trial
Shigellosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rabies. EMBL-EBI & Wellcome Sanger Institute.
- [4]